Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-08-10 Sale |
2021-08-12 4:20 pm |
Fulcrum Therapeutics Inc. | FULC | Moxham Christopher Chief Scientific Officer |
51,785 | $17.6 | $911,416 | 176,073 (Direct) |
View |
| 2021-08-10 Sale |
2021-08-12 4:20 pm |
Fulcrum Therapeutics Inc. | FULC | Stuart Bryan See Remarks |
60,000 | $20.42 | $1,225,000 | 515,142 (Direct) |
View |
| 2021-06-28 Purchase |
2021-06-29 4:16 pm |
Fulcrum Therapeutics Inc. | FULC | Morabito Christopher Chief Medical Officer |
1,100 | $9.16 | $10,076 | 1,100 (Direct) |
View |
| 2021-06-28 Purchase |
2021-06-29 4:16 pm |
Fulcrum Therapeutics Inc. | FULC | Oltmans Curtis Gale SVP, General Counsel |
1,088 | $9.01 | $9,803 | 1,088 (Direct) |
View |
| 2021-06-28 Purchase |
2021-06-29 4:15 pm |
Fulcrum Therapeutics Inc. | FULC | Thomson Peter G. VP Finance & Accounting |
2,300 | $9 | $20,700 | 2,300 (Indirect) |
View |
| 2021-06-28 Purchase |
2021-06-29 4:15 pm |
Fulcrum Therapeutics Inc. | FULC | GERAGHTY JAMES A Director |
10,000 | $9.16 | $91,600 | 90,714 (Direct) |
View |
| 2021-03-15 Sale |
2021-03-17 4:30 pm |
Fulcrum Therapeutics Inc. | FULC | Gould Robert J See Remarks |
10,000 | $12.16 | $121,578 | 506,630 (Direct) |
View |
| 2021-02-22 Sale |
2021-02-24 4:30 pm |
Fulcrum Therapeutics Inc. | FULC | Thomson Peter G. VP Finance & Accounting |
5,000 | $14.72 | $73,582 | 65,683 (Direct) |
View |
| 2021-02-16 Sale |
2021-02-18 4:30 pm |
Fulcrum Therapeutics Inc. | FULC | Gould Robert J See Remarks |
8,215 | $14.27 | $117,197 | 516,630 (Direct) |
View |
| 2021-01-21 Sale |
2021-01-25 4:30 pm |
Fulcrum Therapeutics Inc. | FULC | Thomson Peter G. VP Finance & Accounting |
6,607 | $14 | $92,498 | 15,212 (Direct) |
View |
| 2021-01-20 Sale |
2021-01-22 4:30 pm |
Fulcrum Therapeutics Inc. | FULC | Gould Robert J See Remarks |
10,000 | $12.08 | $120,826 | 524,845 (Direct) |
View |
| 2020-07-08 Sale |
2020-07-09 4:18 pm |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
2,951 | $20 | $59,020 | 209,030 (Direct) |
View |
| 2020-07-08 Sale |
2020-07-09 4:15 pm |
Fulcrum Therapeutics Inc. | FULC | Gould Robert J See Remarks |
2,500 | $20 | $50,000 | 534,845 (Direct) |
View |
| 2020-07-01 Sale |
2020-07-02 4:19 pm |
Fulcrum Therapeutics Inc. | FULC | Cadavid Diego SVP Clinical Development |
1,071 | $18.3 | $19,599 | 65,714 (Direct) |
View |
| 2020-06-30 Sale |
2020-07-01 4:39 pm |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
141 | $20 | $2,820 | 211,981 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2021-12-09 4:15 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Banks Sonja Director |
0 | $0 | 0 (Direct) |
View |
| 2021-11-10 Other |
2021-11-12 5:31 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | LEVIN MARK J Director 10% Owner |
1,000,000 | $0 | 5,046,425 (Indirect) |
View |
| 2021-11-10 Other |
2021-11-12 5:26 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Third Rock Ventures III L.P. Third Rock Ventures GP III L.P. TRV GP III LLC STARR KEVIN P TEPPER ROBERT I 10% Owner |
1,000,000 | $0 | 7,473,794 (Direct) |
View |
| 2021-09-22 Other |
2021-09-24 4:13 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | LEVIN MARK J Director 10% Owner |
1,000,000 | $0 | 6,004,051 (Indirect) |
View |
| 2021-09-22 Other |
2021-09-24 4:13 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Third Rock Ventures III L.P. Third Rock Ventures GP III L.P. TRV GP III LLC STARR KEVIN P TEPPER ROBERT I 10% Owner |
1,000,000 | $0 | 8,389,054 (Direct) |
View |
| 2021-08-10 Exercise |
2021-08-12 4:20 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Moxham Christopher Chief Scientific Officer |
51,785 | $7.84 | 176,073 (Direct) |
View |
| 2021-08-10 Exercise |
2021-08-12 4:20 pm |
N/A 2029-01-21 |
Fulcrum Therapeutics Inc. | FULC | Moxham Christopher Chief Scientific Officer |
51,785 | $0 | 176,073 (Direct) |
View |
| 2021-08-10 Exercise |
2021-08-12 4:20 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Stuart Bryan See Remarks |
60,000 | $7.84 | 515,142 (Direct) |
View |
| 2021-08-10 Exercise |
2021-08-12 4:20 pm |
N/A 2028-12-17 |
Fulcrum Therapeutics Inc. | FULC | Stuart Bryan See Remarks |
60,000 | $0 | 515,142 (Direct) |
View |
| 2021-06-09 Option Award |
2021-06-11 5:11 pm |
N/A 2031-06-08 |
Fulcrum Therapeutics Inc. | FULC | LEVIN MARK J Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-06-09 Option Award |
2021-06-11 5:11 pm |
N/A 2031-06-08 |
Fulcrum Therapeutics Inc. | FULC | Collins James J. Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-06-09 Option Award |
2021-06-11 5:10 pm |
N/A 2031-06-08 |
Fulcrum Therapeutics Inc. | FULC | Ezekowitz Alan Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-06-09 Option Award |
2021-06-11 5:10 pm |
N/A 2031-06-08 |
Fulcrum Therapeutics Inc. | FULC | GERAGHTY JAMES A Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-06-09 Option Award |
2021-06-11 5:10 pm |
N/A 2031-06-08 |
Fulcrum Therapeutics Inc. | FULC | Haviland Kate Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-06-09 Option Award |
2021-06-11 5:10 pm |
N/A 2031-06-08 |
Fulcrum Therapeutics Inc. | FULC | Dorton Katina Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-05-10 Option Award |
2021-05-12 4:30 pm |
N/A 2031-05-09 |
Fulcrum Therapeutics Inc. | FULC | Morabito Christopher Chief Medical Officer |
163,000 | $0 | 163,000 (Direct) |
View |
Ownership |
2021-05-12 4:15 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Morabito Christopher Chief Medical Officer |
0 | $0 | 0 (Direct) |
View |
| 2021-03-31 Option Award |
2021-04-02 4:30 pm |
N/A 2031-03-30 |
Fulcrum Therapeutics Inc. | FULC | Stuart Bryan See Remarks |
350,000 | $0 | 350,000 (Direct) |
View |
| 2021-04-01 Option Award |
2021-04-02 4:30 pm |
N/A 2031-03-31 |
Fulcrum Therapeutics Inc. | FULC | Dunn Judith See Remarks |
215,000 | $0 | 215,000 (Direct) |
View |
Ownership |
2021-04-02 4:15 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Dunn Judith See Remarks |
0 | $0 | 0 (Direct) |
View |
| 2021-02-22 Exercise |
2021-02-24 4:30 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Thomson Peter G. VP Finance & Accounting |
5,000 | $7.84 | 65,683 (Direct) |
View |
| 2021-02-22 Exercise |
2021-02-24 4:30 pm |
N/A 2029-01-21 |
Fulcrum Therapeutics Inc. | FULC | Thomson Peter G. VP Finance & Accounting |
5,000 | $0 | 65,683 (Direct) |
View |
| 2021-02-08 Option Award |
2021-02-10 4:30 pm |
N/A 2031-02-07 |
Fulcrum Therapeutics Inc. | FULC | Moxham Christopher Chief Scientific Officer |
100,000 | $0 | 100,000 (Direct) |
View |
Ownership |
2021-02-10 4:15 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Moxham Christopher Chief Scientific Officer |
0 | $0 | 186,495 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 4:35 pm |
N/A 2031-02-01 |
Fulcrum Therapeutics Inc. | FULC | Gould Robert J See Remarks |
269,390 | $0 | 269,390 (Direct) |
View |
| 2021-01-25 Option Award |
2021-01-27 4:30 pm |
N/A 2031-01-24 |
Fulcrum Therapeutics Inc. | FULC | Stuart Bryan Chief Operating Officer |
134,376 | $0 | 134,376 (Direct) |
View |
| 2021-01-25 Option Award |
2021-01-27 4:30 pm |
N/A 2031-01-24 |
Fulcrum Therapeutics Inc. | FULC | Thomson Peter G. VP Finance & Accounting |
40,000 | $0 | 40,000 (Direct) |
View |
| 2020-12-03 Option Award |
2020-12-07 4:30 pm |
N/A 2030-12-02 |
Fulcrum Therapeutics Inc. | FULC | Ezekowitz Alan Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2020-12-03 Option Award |
2020-12-07 4:30 pm |
N/A 2030-12-02 |
Fulcrum Therapeutics Inc. | FULC | Oltmans Curtis Gale SVP, General Counsel |
153,600 | $0 | 153,600 (Direct) |
View |
Ownership |
2020-12-07 4:15 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Oltmans Curtis Gale SVP, General Counsel |
0 | $0 | 0 (Direct) |
View |
| 2020-09-14 Exercise |
2020-09-14 4:19 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
6,350 | $7.84 | 209,030 (Direct) |
View |
| 2020-09-14 Exercise |
2020-09-14 4:19 pm |
N/A 2029-01-21 |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
6,350 | $0 | 209,030 (Direct) |
View |
| 2020-07-08 Exercise |
2020-07-09 4:18 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
2,951 | $7.84 | 209,030 (Direct) |
View |
| 2020-07-08 Exercise |
2020-07-09 4:18 pm |
N/A 2029-01-21 |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
2,951 | $0 | 209,030 (Direct) |
View |
| 2020-06-30 Exercise |
2020-07-01 4:39 pm |
N/A N/A |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
141 | $7.84 | 211,981 (Direct) |
View |
| 2020-06-30 Exercise |
2020-07-01 4:39 pm |
N/A 2029-01-21 |
Fulcrum Therapeutics Inc. | FULC | Wallace Owen B. Chief Scientific Officer |
141 | $0 | 211,981 (Direct) |
View |